Nephrotic syndrome associated with interferon-β-1b therapy for multiple sclerosis

Clinical and Experimental Nephrology

Volumn 10, Issue 3, 2006, Pages 222-225

  Kumasaka, Ryuichiro ^a   Nakamura, Norio ^a   Shirato, Kenichi ^a   Fujita, Takeshi ^a   Murakami, Reiichi ^a   Shimada, Michiko ^a   Nakamura, Masayuki ^a   Osawa, Hiroshi ^a   Yamabe, Hideaki ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Interferon (IFN) 1b; Multiple sclerosis; Nephrotic syndrome; Proteinuria

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PREDNISOLONE;

ADULT; ANAMNESIS; ANASARCA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; EDEMA; FEMALE; HUMAN; HYPOALBUMINEMIA; KIDNEY BIOPSY; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; NEPHROTIC SYNDROME; PROTEINURIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; BIOPSY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERFERON-BETA; KIDNEY; MULTIPLE SCLEROSIS; NEPHROSIS, LIPOID; PREDNISOLONE;

EID: 33749316873     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-006-0424-9     Document Type: Article

References (13)

1. A Compston A Coles 2002 Multiple sclerosis Lancet 359 1221 31
2. The IFNB Multiple Sclerosis Study Group 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 655 61
3. PRISMS Study Group 1998 Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis Lancet 352 1498 504
4. European Study Group on Interferon β-1b in Secondary Progressive MS 1998 Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1491 7
5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group 2001 Randomized controlled trial of interferon-beta-1a in secondary progressive MS Neurology 56 1496 504
6. A Bar-Or EML Oliveira DE Anderson DA Hafler 1999 Molecular pathogenesis of multiple sclerosis J Neuroimmunol 100 252 9
7. BD Trapp L Bo S Mork A Chang 1999 Pathogenesis of tissue injury in MS lesions J Neuroimmunol 98 49 56
8. H Jiang R Milo P Swoveland KP Johnson H Panitch S Dhib-Jalbut 1995 Interferon β-1b reduces interferon γ-induced antigen-presenting capacity of human glial and B cells J Neuroimmunol 61 17 25
9. VW Yong S Chabot O Stuve G Williams 1998 Interferon beta in the treatment of multiple sclerosis: mechanisms of action Neurology 51 682 9
10. K Nakao H Sugiyama E Makino H Matsuhara A Ohmoto T Sugimoto 2002 Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma Nephron 90 498 500
11. I Gotsman M Elhallel-Darnitski Z Friedlander YS Haviv 2000 β-Interferon-induced nephrotic syndrome in a patient with multiple sclerosis Clin Nephrol 54 425 6
12. MR Tola LM Caniatti D Gragnaniello M Russo N Stabellini E Granieri 2003 Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a J Neurol 250 768 9
13. A Auty A Saleh 2005 Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a Can J Neurol Sci 32 366 8